OLUFISAYO OMOBO: Open Payments
NPI 1962284471 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 9 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $265 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 3 | $321 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $226 |
| Neurocrine BioSciences, Inc. | 1 | $140 |
| Supernus Pharmaceuticals, Inc. | 1 | $114 |
| E.R. Squibb & Sons, L.L.C. | 1 | $76 |
| Lundbeck LLC | 1 | $15 |
Products named: ABILIFY MAINTENA, CAPLYTA, INGREZZA, Qelbree, COBENFY, ABILIFY ASIMTUFII.
Industry payments across DC — which companies pay providers there.
